BofA warns Fed risks policy mistake with early rate cuts
Mary Anne Heino, a director at Lantheus Holdings, Inc. (NASDAQ:LNTH), a $6.89 billion medical diagnostics company with an "EXCELLENT" financial health rating according to InvestingPro, recently sold a significant portion of her holdings in the company. According to a recent SEC filing, Heino sold a total of 52,107 shares of Lantheus common stock. The sales were executed at prices ranging from $92.29 to $95.91 per share, amounting to a total transaction value of approximately $5,010,733. This transaction comes as the stock has delivered an impressive 52.34% return over the past year.
These transactions were conducted under a Rule 10b5-1 trading plan, a pre-established plan that allows insiders to sell stocks at predetermined times to avoid potential accusations of insider trading. The sales were part of a strategy to cover tax liabilities associated with the vesting of previously granted restricted stock.
Following these sales, Heino holds 440,399 shares directly, while additional shares are held indirectly through a Grantor Retained Annuity Trust.
In other recent news, Lantheus Holdings reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $1.59, compared to the forecast of $1.55, and revenue reaching $391.1 million, exceeding the expected $377.24 million. This positive earnings performance was largely driven by the strong sales of their flagship product, Polarify, which contributed significantly to the company’s revenue growth. For the full year, Lantheus achieved a revenue of $1.534 billion, marking an 18.3% increase from the previous year.
Mizuho (NYSE:MFG) Securities adjusted its financial outlook on Lantheus, lowering the stock target price from $150 to $140 while maintaining an Outperform rating. This adjustment followed the company’s earnings report and initial 2025 guidance, which includes projected growth for Pylarify and an updated U.S. PSMA market forecast. Lantheus has also set a revenue guidance of $1.545 billion to $1.610 billion for 2025, indicating an anticipated growth of 1-5%.
Lantheus’ recent strategic moves include the pending acquisitions of Life Molecular Imaging and Evergreen Medical (TASE:BLWV) Services, which are expected to enhance the company’s capabilities in radiopharmaceuticals. These transactions are projected to close in the second half of the year and are not yet factored into the 2025 financial guidance. Analysts from Mizuho expressed confidence in Lantheus’ ability to navigate market challenges and achieve its commercial targets, particularly with its leading product, PYLARIFY.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.